Our mission is to contain rapidly evolving viruses with vaccines that activate both branches of the immune system.
Transmucosis has built the only protein-based vaccination platform that will activate both mucosal and systemic branches of the immune system.
We believe that dual immune activation will be required to contain rapidly evolving viruses like SARS-CoV-2, and other pathogens including Influenza and RSV.
Transmucosis is exploiting the unique properties of the FcRn receptor to actively transport its vaccine molecules across epithelial cell barriers.
Photo credit: CDC
The challenge for current vaccines is to keep pace with the rapidly evolving SARS-CoV-2 virus. Transmucosis offers a promising solution to contain COVID-19 by combining multiple variant antigens in a single vaccine molecule.
Cookie | Duration | Description |
---|---|---|
cookielawinfo-checkbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
cookielawinfo-checkbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
cookielawinfo-checkbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |